News

November 19, 2018

Abdominal Chemotherapy Perfusion Effective on Treatment-resistant, Recurrent OC in Phase 2 Study

News

Localized chemotherapy perfusion in the abdomen showed efficacy in patients with treatment-resistant and recurrent ovarian cancer, according to preliminary results of an ongoing Phase 2 clinical study. A subset ... Read more

November 16, 2018

FDA Gives Priority Review to Lynparza as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review the use of Lynparza (olaparib) tablets as a maintenance treatment for women newly diagnosed with advanced ovarian cancer, ... Read more

November 12, 2018

Docetaxel Nanoparticle CPC634 in Phase 2 Trial for Platinum-resistant OC

News

Cristal Therapeutics has begun patient dosing in its Phase 2a trial evaluating CPC634 — the chemotherapy docetaxel, delivered in nanoparticles — in patients whose ovarian cancer has become resistant to ... Read more

November 9, 2018

Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests

News

Ovarian cancer patients who receive Zejula (niraparib) after responding to platinum-based chemotherapy experience fewer adverse effects in a real-world setting than was reported in a Phase 3 clinical trial, a ... Read more

November 5, 2018

Adding GEN-1 to Standard Chemotherapy Halts Advanced Ovarian Cancer Progression, Phase 1b Trial Shows

News

A combination of Celsion’s DNA-based immunotherapy GEN-1 and standard chemotherapy halted disease progression in women with stage III/IV ovarian cancer eligible for surgery, according to results of a Phase 1b trial. ... Read more

November 2, 2018

Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers

News

Compugen has entered into a clinical trial collaboration with Bristol-Myers Squibb (BMS) to evaluate the safety and preliminary effectiveness of its investigational immunotherapy COM701 in combination with BMS’ Opdivo (nivolumab), in ... Read more

October 29, 2018October 29, 2018

Cancer Cells from Fallopian Tube Communicate with Healthy Ovaries to Promote Cancer Growth, Researchers Find

News

Cancer cells from the fallopian tube — the precursors of ovarian cancer — communicate with healthy ovaries and trigger the release of a hormone called norepinephrine, creating an environment ... Read more

October 26, 2018

Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients

News

The Phase 1a/1b trial evaluating Five Prime Therapeutics‘ checkpoint inhibitor FPA150 in patients with advanced solid cancers has begun dosing patients ahead of schedule, the company announced. FPA150 is an antibody ... Read more

October 24, 2018

Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows

News

Ovarian cancer patients with BRCA mutations who received Lynparza (olaparib) maintenance treatment after first-line platinum-based chemotherapy lived three years longer without signs of disease worsening than patients who received ... Read more

October 22, 2018

First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma

News

MaxCyte has begun dosing participants in a Phase 1 trial to assess its lead CAR T-cell therapy, MCY-M11, for the treatment of advanced ovarian cancer and peritoneal mesothelioma patients who ... Read more

Pin It on Pinterest